BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22157030)

  • 1. Ga-68 DOTA-NOC uptake in the pancreas: pathological and physiological patterns.
    Krausz Y; Rubinstein R; Appelbaum L; Mishani E; Orevi M; Fraenkel M; Tshori S; Glaser B; Bocher M; Salmon A; Chisin R; Gross DJ; Freedman N
    Clin Nucl Med; 2012 Jan; 37(1):57-62. PubMed ID: 22157030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine tumor imaging with 68Ga-DOTA-NOC: physiologic and benign variants.
    Kagna O; Pirmisashvili N; Tshori S; Freedman N; Israel O; Krausz Y
    AJR Am J Roentgenol; 2014 Dec; 203(6):1317-23. PubMed ID: 25415711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study.
    Naswa N; Sharma P; Kumar A; Nazar AH; Kumar R; Chumber S; Bal C
    AJR Am J Roentgenol; 2011 Nov; 197(5):1221-8. PubMed ID: 22021518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of 68Ga-DOTA-NOC PET/CT in evaluating neuroendocrine tumors: real-world experience from two large neuroendocrine tumor centers.
    Haidar M; Shamseddine A; Panagiotidis E; Jreige M; Mukherji D; Assi R; Abousaid R; Ibrahim T; Haddad MM; Vinjamuri S
    Nucl Med Commun; 2017 Feb; 38(2):170-177. PubMed ID: 27922538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
    Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
    Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.
    Kroiss A; Putzer D; Decristoforo C; Uprimny C; Warwitz B; Nilica B; Gabriel M; Kendler D; Waitz D; Widmann G; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):514-23. PubMed ID: 23291643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.
    Ambrosini V; Tomassetti P; Castellucci P; Campana D; Montini G; Rubello D; Nanni C; Rizzello A; Franchi R; Fanti S
    Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1431-8. PubMed ID: 18418596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT.
    Prasad V; Ambrosini V; Hommann M; Hoersch D; Fanti S; Baum RP
    Eur J Nucl Med Mol Imaging; 2010 Jan; 37(1):67-77. PubMed ID: 19618183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET.
    Fanti S; Ambrosini V; Tomassetti P; Castellucci P; Montini G; Allegri V; Grassetto G; Rubello D; Nanni C; Franchi R
    Biomed Pharmacother; 2008 Dec; 62(10):667-71. PubMed ID: 18358680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of [
    Yadav D; Ballal S; Yadav MP; Tripathi M; Roesch F; Bal C
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):860-869. PubMed ID: 31754796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with ¹¹¹In-DTPA-octreotide (OctreoScan®).
    Krausz Y; Freedman N; Rubinstein R; Lavie E; Orevi M; Tshori S; Salmon A; Glaser B; Chisin R; Mishani E; J Gross D
    Mol Imaging Biol; 2011 Jun; 13(3):583-593. PubMed ID: 20652423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency and significance of physiological versus pathological uptake of 68Ga-DOTATATE in the pancreas: validation with morphological imaging.
    Mapelli P; Tam HH; Sharma R; Aboagye EO; Al-Nahhas A
    Nucl Med Commun; 2014 Jun; 35(6):613-9. PubMed ID: 24686250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidental finding of a breast carcinoma on Ga-68-DOTA-1-Nal3-octreotide positron emission tomography/computed tomography performed for the evaluation of a pancreatic neuroendocrine tumor: A case report.
    Sampaio Vieira T; Borges Faria D; Souto Moura C; Francisco E; Barroso S; Pereira de Oliveira J
    Medicine (Baltimore); 2018 Sep; 97(36):e11878. PubMed ID: 30200073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uptake in the pancreatic uncinate process on the 111In-octreotide scintigraphy: How to distinguish physiological from pathological uptake?
    Ait Boudaoud A; Verges B; Petit JM; Tatulashvili S; Cochet A; Humbert O
    Nucl Med Commun; 2017 Sep; 38(9):737-743. PubMed ID: 28704340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is ⁶⁸Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour?
    Ambrosini V; Campana D; Nanni C; Cambioli S; Tomassetti P; Rubello D; Fanti S
    Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1278-83. PubMed ID: 22584487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours.
    Virgolini I; Gabriel M; Kroiss A; von Guggenberg E; Prommegger R; Warwitz B; Nilica B; Roig LG; Rodrigues M; Uprimny C
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2072-83. PubMed ID: 27174220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions.
    Prasad V; Baum RP
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):61-7. PubMed ID: 20168287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with octreotide in patients with well-differentiated neuroendocrine tumors of the ileum: prognostic stratification with Ga-68-DOTA-TATE positron emission tomography.
    Koch W; Auernhammer CJ; Geisler J; Spitzweg C; Cyran CC; Ilhan H; Bartenstein P; Haug AR
    Mol Imaging; 2014; 13():1-10. PubMed ID: 24824963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pitfall in follow-up imaging of pancreatic neuroendocrine tumor by somatostatin receptor PET.
    Reindl O; Loidl A; Franz B; Hofer JF; Pichler R
    Neuro Endocrinol Lett; 2013; 34(4):273-4. PubMed ID: 23803870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
    Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
    J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.